Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHealing Innovations

About this trial

This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years.

First-ever ischemic or hemorrhagic stroke confirmed by medical record.

3 months to 5 years post-stroke at time of enrollment.

Presence of lower-extremity motor impairment limiting walking function.

Disqualifiers

Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).

Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).

Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.

Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Rise&Walk InHome by Healing Innovations

    Device

    The Rise\&Walk InHome (RWH) is a robotic gait training technology that allows for high repetition stepping practice safely in the home. A RWH device will be placed in the homes of participants in the treatment group. If needed, refresher training will be provided upon installation, and device settings will be configured based on the participant's most recent screening session. Participants in the treatment group will be instructed to use the RWH for 30 minutes per day, four times per week. Participants can achieve 30 minutes in ≥ 10 minute bouts throughout the day or if rest breaks are needed within the session. Individualized parameters will be established at Kessler, and participants will be educated on self-progression using the RPE monitor to track effort and progress.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Treatment Group: Rise&Walk InHome Walking GroupActive comparator 1 intervention
Group B: Control Group: Usual CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

6-minute walk test

A standardized submaximal exercise test that measures functional exercise capacity by recording the total distance a participant can walk on a flat, straight course in six minutes. The primary outcome is walking distance, typically recorded in meters. Higher distances indicate better functional mobility and aerobic capacity, whereas shorter distances reflect greater impairment or reduced endurance.

Time frame
0,4,8,12 weeks

Secondary outcomes

1

ten-meter walk test

A performance-based measure of walking speed in which participants are timed while walking a 10-meter distance at their comfortable and/or fastest safe speed on a flat, level surface. Walking speed (m/s) is calculated by dividing distance in meters by time in seconds, often using the middle 6 meters to minimize acceleration and deceleration effects. Higher walking speeds indicate better functional mobility and gait performance, whereas slower speeds reflect greater gait impairment and reduced community ambulation capacity. Slower gait speeds have been associated with increased fall risk and reduced ability to safely navigate community environments.

Time frame
0,4,8,12 weeks
2

Daily Step Count

Cumulative change in daily step count using a Step Tracking Device

Time frame
Through study completion, on average 13 weeks.
3

Short Form (36) Health Survey

A 36-item self-report questionnaire assessing health-related quality of life across eight domains: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality (Energy/Fatigue), Social Functioning, Role Limitations due to Emotional Problems, and Mental Health. Items are scored and transformed to yield domain scores ranging from 0 to 100, with higher scores indicating better health status and quality of life (less disability/fewer limitations). Summary scores (Physical Component Summary and Mental Component Summary) may also be calculated, with higher scores reflecting better overall physical or mental health.

Time frame
0,4,8,12 weeks
4

Modified version of the Intrinsic Motivation Inventory (IMI) designed to include 26 relevant items from the full set of 45 items in the original questionnaire.

Modified Intrinsic Motivation Inventory (IMI) for Rise\&Walk InHome (RWH): An 18-item self-report questionnaire adapted from the Intrinsic Motivation Inventory to assess participants' motivation and user experience related to using the RWH device at home. Items are rated on a 7-point Likert scale (1 = Strongly Disagree to 7 = Strongly Agree). The measure includes six subscales: Interest/Enjoyment, Perceived Competence, Effort/Importance, Pressure/Tension, Value/Usefulness, and Usability \& Feasibility. Pressure/Tension items are reverse-scored so that higher scores reflect lower pressure or stress. Subscale scores are calculated by summing (or averaging) the items within each domain after reverse scoring, yielding a possible range of 1-7 for each item and higher scores indicating greater intrinsic motivation, perceived competence, effort, perceived value, usability, and lower pressure/tension related to RWH use.

Time frame
4,8,12 weeks

Other outcomes

1

Rating of Perceived Exertion (RPE) - Modified BORG

RPE will be measured for the treatment group only during their walking sessions. The technology software will use the Borg RPE scale. Responses for each domain will be rated using the revised category-ratio scale (0 \[nothing at all\] to 10 \[maximal\] ordinal response scale).

Time frame
4,8,12 weeks
2

Walking compliance

e will model walking compliance as a proportion, with cumulative number of successful events from a series of successes and failures divided by the total number of assessments. The RWH system has a mobile application that shares usage data with an online HIPPA-compliant dashboard, which will be used to monitor walking compliance. Walking sessions on the RWH system will be performed 4 times per week over the course of the study. We will require a minimum of 30-minute sessions for successful participation in each walking routine.

Time frame
4,8,12 weeks
3

System Usability Scale

Ease of use will be measured for the treatment group using the System Usability Scale (SUS). Each of the 10 questions on the SUS will be answered on a 5 pt ordinal scale, with responses ranging from "strongly agree" to "strongly disagree". The final possible scores ranging from 0 to 40 will be transformed to a 0 to 100 scale, based on the assumption that each question carries equal weight.

Time frame
4,8,12 for treatment group
4

Cumulative incidence of adverse events

Adverse events (AEs) will be classified according to the International Classification of Diseases Version 10 (ICD-10) or another validated coding system for medical complications. Individual AE types will also be summarized.

Time frame
Through Study Completion, approximately 12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Healing Innovations

Lead sponsor

Kessler Foundation

Collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: